Alligator Energy to raise $1.75M to fund uranium drilling

|

Published 29-JUN-2018 10:22 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Alligator Energy (ASX:AGE) has received firm commitments for a placement of $1.75 million to institutional and high net worth investors.

According to AGE, demand was high and the offer was oversubscribed.

Capital raised from the placement will be used to fund AGE’s proposed drilling program at the TCC4 uranium prospect in the Northern Territory.

AGE is an ASX-listed explorer centred on uranium and energy-related minerals — primarily cobalt-nickel. The company is focused on the discovery of large economic high-grade energy-related metal deposits (uranium, nickel, cobalt) with clear pathways for approval and development.

With mounting uranium interest and favourable sentiment building around uranium equities, and given the current dry season, now is a good time for AGE to initiate drilling of its primary uranium target.

Funds of up to $1.5 million will be allocated to restart exploration work and undertake drilling at the TCC4 prospect. AGE will also allocate funds to advance other promising uranium targets on its tenements within Arnhem Land.

It’s worth noting that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.

After several years of work, the TCC4 prospect in the ARUP contains the best quality uranium target outlined by AGE’s proprietary pathfinder and modified SAM undercover exploration techniques. AGE said it believes that this prospect represents the best complete undercover target, with close similarities to the major uranium deposits of the ARUP.

A significant combined track and helisupported drilling program is required to test the concept, and a 2,400 to 3,000 metre drilling program is planned.

AGE this week reopened the Myra drilling camp in Arnhem Land, and will be commencing track opening works.

Alligator’s acting CEO, Greg Hall, said: “The company’s view is that this placement opportunity represents immediate value in on-ground drilling work this year on our primary target in the Alligator Rivers Uranium Province (ARUP), rather than next year under a potential strategic partner arrangement.”

“Alligator has advanced the TCC4 prospect to a drill-ready stage, with several years of undercover pathfinder work to determine the most likely locations for mineralisation beneath the sandstone cover.”

“We have already commenced dry season access work in ARUP and have a field team established at Myra Camp, planned as part of access and asset maintenance under Traditional Owner (TO) agreements. Initial logistical preparations have commenced and the appropriate compliance documents have been lodged with the relevant stakeholders,” added Hall.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X